Skystar Bio-Pharmaceutical (OTC BB: CGPN), a leading Bio-Pharmaceutical Company in China, today announced that its Anti-Avian Influenza Medicine (H5N1) has passed its first phase of testing. Additionally, Skystar has established a task force to prevent, respond to and control outbreaks of the Avian Influenza A (H5N1) Virus.
